Subscribe to news

Press Releases

16.08.2013
The Human Stem Cells Institute, today announced its unaudited unconsolidated results for the first half of 2013 in accordance with the Russian Accounting Standards (RAS)
20.06.2013
OJSC HSCI, today announced the results of the Annual General Shareholders’ Meeting (AGM) held on June 20, 2013, in Moscow.
20.05.2013
OJSC HSCI, today announced the decision of the Company’s Board of Directors on the agenda of the Annual General Shareholders’ Meeting upon the results of 2012.
16.05.2013
The Human Stem Cells Institute, one of Russia’s leading biotech companies, today announced its results for the first quarter of 2013 in accordance with the Russian Accounting Standards (RAS)
08.05.2013
The Human Stem Cells Institute, one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, announced its consolidated results for 2012 under IFRS
30.04.2013
The Human Stem Cells Institute held a public presentation of the company’s strategy and business plan for the period from 2013 to 2017.
30.04.2013
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, announced its plans for a roadshow for the purpose of attracting an institutional investor.
25.04.2013
The Human Stem Cells Institute, today announced the decision of the Company’s Board of Directors on convocation of the Annual General Shareholders’ Meeting upon the results of 2012.
03.04.2013
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its audited unconsolidated results for 2012 in accordance with the Russian Accounting Standards (RAS)
26.03.2013
Human Stem Cells Institute OJSC (“HSCI”, MICEX: ISKJ), one of the leading Russian biotech companies, today announced that an agreement has been signed to supply the Russian pharmaceutical company Sotex Pharm Firm with the innovative drug Neovasculgen®, developed by HSCI for treatment of Peripheral Arterial Disease.